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1 Model Equations 
 
The model includes compartments for susceptible PWID  and chronically infected PWID . The model population was 
stratified by incarceration status: never incarcerated, currently incarcerated, recently released (within the last 6 months) and 
previously incarcerated but not in last 6 months (i=0, 1, 2, 3 respectively). The model population was further stratified by duration of 
injecting: recent and non-recent PWID, <5 years and > 5 years injecting respectively (d=0 or 1 respectively). 
 
New PWID enter the model at rate  as uninfected, recent PWID with a fixed proportion pi of entrants entering into each 
incarceration state. PWID transition from recent to non-recent PWID with rate 0.2 per year and leave all compartments through 
death or permanent cessation of injecting with rate . 
 
PWID in the community are (re)incarcerated with rates dependent upon duration of injecting and incarceration state, with never 
incarcerated PWID experiencing incarceration with rate  and recently released and previously incarcerated PWID experiencing a 
re-incarceration rate . Incarcerated PWID are released from prison with rate , with a proportion  ; representing a 2-week 
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period of elevated risk of drug-related deaths post release, since this elevated risk diminishes 3-4 weeks after release) of these removed from 
the model to simulate increased mortality amongst drug users in the short time after their release from prison with the reminder 
entering the recently released compartment. PWID spend an average of 6 months in the recently released compartment before 
transitioning to the previously incarcerated compartment. 
 
All PWID are initially susceptible  and become HCV infected with a per-capita rate, λs,d, specific to the duration of injecting and 
incarceration status (in community or prison, denoted by s=0 or 1 respectively). Forces of infection are given by  for incarcerated 
PWID (constant across all duration of injecting) and  for community PWID, specific to duration of injecting (d=0 for recent PWID 
and d=1 for non-recent PWID). The force of infection amongst recently released PWID is heightened by a factor . Incarcerated 
PWID can only transmit HCV to other incarcerated PWID and similarly community PWID can only transmit HCV to other PWID in 
the community. 
 
A proportion ( ) of PWID spontaneously clear their acute infection and remain susceptible , with the remaining proportion 
 proceeding to the chronically infected compartment .  and  chronically infected PWID are treated in the 
community and prison respectively, with a proportion  immediately achieving SVR and transitioning to the susceptible 
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compartment , whilst the remainder  fail treatment and remain chronically infected. If the number of PWID to be 
treated in the community exceed the number of chronically infected PWID than all are treated, whilst if the number to be treated 
exceed the number of eligible (42% corresponding to the proportion with sentence lengths of 16 weeks or greater), chronically 
infected, incarcerated PWID, then all eligible PWIDs are treated. Community and prison treatment rates in the model equations are 
given by ) and  respectively. No immunity is assumed because data are uncertain(1) and previous analyses suggested 
it is likely to have little effect on model projections(2, 3).  
 
We model HCV treatment as instantaneous, because of the short duration of DAA treatment regimens(4). Although the average 
sentence length for PWID (5.8 months) was shorter than the duration of HCV treatment prior to 2015 (24-48 weeks), treatment 
rates for peg-interferon and ribavirin in prison were very low; at most 16 PWID were treated a year since the national scale-up in 
2008. We use observed SVR rates amongst prisoners treated during this time which accounts for any loss to follow up due to 
individuals leaving prison before finishing treatment, which was not great because treatment was generally only given to those with 














































Similarly for treatments in prison: 
 
2 Parameterising the incarceration component of the model 
An adapted incarceration model without HCV transmission, ‘deaths’ and ‘births’ (model schematic in Supplementary Figure 1) was 
used to calibrate the incarceration component of the model to data from NESI on the proportion of community PWID with 0, 1 or 
multiple previous incarcerations. This adapted model stratified PWID by incarceration status (community or prison) and the number 
of previous incarcerations (0, 1 and 2 or more in the community; and 0 or 1 or more in prison). PWID are incarcerated and 
reincarcerated with rates  and , respectively, which depend on whether PWID are recent (<5 years injecting) or non-recent (>5 
years injecting) initiates of injecting. PWID are released from prison at a fixed rate , with a proportion ( ) of those being 
released leaving the model due to increased mortality post-release. Using this adapted model, 1000 PWID were followed 
throughout their injecting ‘career’ for 20 years from the onset of injecting, with a proportion  of the 1000 PWID starting in each 
compartment. These proportions are then used to find the proportion of PWID that initiate injecting in each incarceration 
compartment in the full model. 
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Supplementary Figure 1: Schematic for the incarceration sub-model. 
 
We used an Approximate Bayesian computation sequential Monte Carlo (ABC SMC) algorithm(6) to obtain a sample of 
incarceration-related parameter sets that fit the NESI incarceration data sufficiently well whilst also giving rise to a total PWID 
population size that is within the latest estimated range for Scotland(7) (more details below). Supplementary Figure 2 shows an 






Supplementary Figure 2: Example of ABC SMC fit, along with the data points used in the fitting procedure with their 95% confidence intervals. 
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2.1 The ABC SMC Algorithm 
The aim of ABC methods is to infer posterior distributions where likelihood functions are difficult to compute/write down. In standard 
ABC methods, a set of parameters, θ*, is sampled from a prior distribution, π(θ), which is used in the model to generate a dataset x* 
which is compared to experimental/observed data x0 using a distance function, d(x*,x0). If the distance between the generated data 
and observed data is less than a predetermined tolerance, ε, the sample, θ*, is accepted. The output is a sample from the 
distribution π(θ | d(x0,x*) ≤ ε), which if ε, is sufficiently small is a good approximation to the posterior distribution, π(θ|x0).  
 
We utilized an ABC SMC algorithm to avoid possible issues with traditional ABC methods such as the ABC rejection sampler or the 
ABC MCMC algorithm, requiring less sampling to obtain the final population size and hence taking less time. In ABC SMC, a 
population of N sampled parameter sets, {θ(1), θ(2), …θ(3)}, sampled from the prior distributions, π(θ) are propagated through a 
sequence of intermediate distributions, π(θ | d(x0,x*) ≤ εi), i=1 … T-1, until it represents a sample from the target distribution π(θ | 
d(x0,x*) ≤ εT). The tolerances, εi are chosen so that ε1 > ε2 ... > εT.  The ABC SMC in its general form, as outlined in (6) proceeds as 
follows, 
(STEP 1) Initialize tolerances,  ε1 ... εT. 




(STEP 2) Set the particle indicator i=1. 
 
(STEP 3) If t=0 sample θ** independently from π(θ). 
Else, sample θ* from the previous population { } with weights  and perturb the particle to obtain θ** ~ Kt (θ | θ*), 
where Kt is a perturbation kernel. 
If π(θ**) = 0, return to STEP 3 
Simulate a candidate dataset, x*, using the model. 
If d(x0,x*) ≥ εt, return to step 3. 
 






 if i<N , set i=i+1, go to step 3. 
 
(STEP 5) Normalize the weights. 
If t < T, set t=T+1, go to step 2. 
 
2.2 ABC SMC to sample incarceration parameters 
In our implementation, we sought a sample of parameter sets that would approximately be from the posterior distribution π(θ |x0)		 . 
The data, x0 (see Supplementary Table 1), consists of data points by {  which are the proportions of PWID in the community that 
have never been incarcerated (i=0), been incarcerated once (i=1), and been incarcerated multiple times (i=2) by duration injecting, 
t. We took the distance function to be the sum of the square errors on the logarithmic scale, i.e. , 






Supplementary Table 1: Data on the proportions of PWID with zero, one or multiple incarcerations by duration of injecting, used in the ABC SMC. 
 Proportion of PWID who have 
Duration of injecting (Years) Never been incarcerated Been incarcerated once Been incarcerated multiple 
times 
<=1 83.07 8.85 8.07 
>1 and <=2 70.17 14.09 15.75 
>2 and <=3 53.13 17.19 29.69 
>3 and <=4 57.29 10.76 31.94 
>4 and <=5 45.05 11.50 43.45 
>5 and <=8 41.85 13.92 44.24 
>8 and <=11 34.83 11.97 53.21 
>11 and <=14 28.04 11.03 60.93 
>14 and <=17 27.61 11.67 60.74 
>17 and <=20 20.16 10.47 69.37 
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In order to ensure parameter sets gave rise to expected population sizes (within a recently estimated range(7)), a sampled 
parameter set, θ**, was accepted to be part of population t, if the distance between the generated data and observed data was less 
than εt, using the above distance function, and the model population size was within the range [11500, 18600]. For each parameter 
set, the model population size was found by calibrating the number of incarcerated PWID at equilibrium to that suggested by 
Scottish prison data; the proportion of Scottish prisoners who are current PWID (P – sampled as part of the ABC SMC regime) and 
the average number of people imprisoned at any one time in Scotland (7853 in 2010/11 (9)).  
Supplementary Table 2: Prior distributions and perturbation kernels for the ABC SMC algorithm used in the uncertainty analysis. 
Parameter Symbol Prior Distribution Perturbation 
Kernel 
Source & Comments 
Death rate (per year) μ1 Sampled from a Poisson 
distribution with mean (10), with 





Average duration Injecting 
(years) 
μ2 Uniform on (5,20) Uniform 
(-0.375, 0.375) 
(11) 
Factor increase in mortality 
for 2 weeks following 
μ* Lognormal with parameters 
(2.0053,0.1393) truncated to 95% 
Uniform 
(-0.105,0.105) 
(12)   
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prison release confidence interval [5.7,9.9] 
Percentage of prison 
population that are current 
PWID 
P Normal with parameters (0.19, 





Estimated from prison Survey 
Proportion of PWID 
initiating injecting 
 Dirichlet distribution with 
parameters (10,1,1,1,1) 
 Obtained through model fitting. 
 
In the final model which does not stratify incarceration 
history into incarcerated once and twice or more:  
 p2 and  p4 are combined to give the proportion of 
PWID initiating in prison 
 p3 and p5 are combined to give the proportion of 
PWID initiating in the community having been 
incarcerated – a random proportion of which have 






 Community, never 
incarcerated 
p1  Uniform  
(-0.04 , 0.04) 
 Incarcerated for first 
time 
p2  Uniform  
(-0.04 , 0.04) 
 Community, 
incarcerated once 
p3  Uniform  
(-0.04 , 0.04) 
 Incarcerated for 2nd or 
more time 
p4  Uniform  
(-0.04 , 0.04) 
 Community, 
incarcerated twice or 
more 
p5  Uniform  
(-0.04 , 0.04) 
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Incarceration rates per 
year 
γ   Obtained through model fitting 
 <5 years 
injecting 
Uniform on (0,0.25) Uniform 
(-0.025,0.025) 
 >5 years  
injecting 
Uniform on (0,0.25) Uniform 
(-0.025,0.025) 
Re-incarceration rates per 
year 
δ   Obtained through model fitting 
 <5 years 
injecting 
Uniform on (0,1) Uniform 
(-0.05,0.05) 
 >5 years  
injecting 
Uniform on (0,1) Uniform 
(-0.05,0.05) 
Release Rate τ Normal with parameters (0.48, 









To ensure the gradual transition between populations, we set the tolerances to be equally spaced on the log-scale between 20 and 
0.35 with 50 iterations of the algorithm (i.e. T=50), choosing εT to be 0.35 because a single best fit to the data gives an error 
(defined by the distance function) of 0.25. Prior distributions and perturbation kernels for each parameter sampled by the ABC SMC 
are shown in Supplementary Table 2. 
 
 
3 Parameterising the transmission component of the model 
 
For each of the 10,000 parameter fits for the incarceration sub-model, parameter values for the proportion of infections that 
spontaneous clear, SVR rates for PEG-IFN/RBV treatments and the increased risk amongst recently released PWID were sampled 
from parameters distributions (Table 2). For each of these parameter sets, HCV incidences amongst recent and non-recent 
community PWID and incarcerated PWID were sampled from the distribution of incidence rates after removing those falling outside 
the 2.5 and 97.5 percentiles (section 3.2) and HCV transmission rates amongst recent and non-recent community PWID and 
incarcerated PWID were calibrated to these sampled values using a pattern-search algorithm (implemented in Matlab_R2015b). If 
these parameter sets projected HCV prevalence amongst community PWID and incarcerated PWID lay within the 95% confidence 




3.1 Increased Risk amongst recently incarcerated PWID 
 
Using data from 2 survey years (2008/9 and 2013) in the needle exchange surveillance initiative(13-15) (NESI) involving 1,717 anti-
HCV negative PWID from across Scotland, a logistic regression was employed to investigate the association between recent 
incarceration (in the last 6 months) and recent HCV infection. Recent infection was defined as those who were tested anti-HCV 
negative and HCV-RNA positive on dried blood spot, whilst duration of injecting, categorized by less than or more than 5 years, 
was controlled for as a possible confounder. The central estimate of the generated adjusted odds ratio (i.e. 2.30; 95% CI 0.97-5.46) 
was taken to be the risk factor for recently incarcerated PWID in the baseline model, whilst the corresponding 95% confidence 
interval was utilized in the uncertainty analysis.  
 
 
3.2 HCV incidence amongst recent and non-recent PWID 
Estimates for HCV incidence amongst current community and all incarcerated PWID along with 95% confidence intervals 
(Supplementary Table 3) were derived using the methods below, using data from NESI 2008(13) and the prison survey(16). 
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Community current PWID were defined to be those that injected in the last 6 months. Incidence was estimated amongst all 
incarcerated PWID due to possible temporary cessation during incarceration. HCV incidence was derived using the formula, 
 
where T is the estimated duration of the window period (where the virus is detectable but prior to the formation of antibodies), n is 
the number of recent infections as defined above, and N is the number of anti-HCV negatives (susceptibles). A point estimate was 
derived using the mean duration of the window (51 days), while 95% confidence intervals were derived by a bootstrapping method 
in which: 
(i) 10000 values were sampled from a normal distribution relating to the window period (mean 51 days, variance 56 days), T, 
and a beta distribution (n, N-n) corresponding to the proportion of recent infections, p. 
(ii) The above formula for incidence was used with each sampled pair from (i), using p in place of n/N, to generate a distribution 
of incidence rates. 
(iii) Taking 2.5th and 97.5th percentile values from (ii) to generate upper and lower confidence limits. 
Supplementary Table 3: Derived HCV incidence amongst recent and non-recent current community PWID and incarcerated PWID. 
 Recent Infections (n) Susceptibles  
(N) 
Derived Incidence (using 51 days as duration of window 
period) 
Derived 95% Confidence interval 
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Recent Community PWID (<5 years 
injecting): 2008 
13 392 23.1 11.9-40.6 
     
Non-recent community PWID (>5 years 
injecting):2008 
7 539 10.5 4.8-19.5 
     
Incarcerated PWID (2010/11) 3 481 4.5 0.9-11.6 
 
 
4 Uncertainty in Model Projections 
We undertook a linear regression analysis of covariance (ANCOVA) in order to determine which parameter uncertainties are 
influential in the model projections of the 15-year impact of scaling up annual prison treatment rates so that 80% of chronically 
infected PWID with at least 16-week sentences are treated on prison entry from 2015. The proportion of each model outcome’s 
sum-of-squares contributed by each parameter was calculated to estimate the importance of individual parameters to the overall 










Contribution to the total uncertainty in the model projections of the 15-year impact of 
scaling up annual prison treatment rates  
On HCV incidence (%) On chronic HCV prevalence (%) 
Incarceration rates per year γ 
  
 




Non-recent PWID (>5yrs injecting) 
 
1.280 1.409 
Reincarceration rates per year δ 
  
 




Non-recent PWID (>5yrs injecting) 
 
7.503 7.660 




Never incarcerated p1 0.124 0.175 
 
Incarcerated p2 0.124 0.175 
 
Recently released p3 0.124 0.175 
 
Previously Incarcerated p4 0.124 0.175 
Release rate from prison per year τ 0.182 0.253 
Increased risk amongst recently released PWID (<6 months since 
release) 
η 17.292 11.894 
Proportion of new infections that spontaneously clear α 8.160 8.882 
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Percentage of prison population that are current PWID P 0.000 0.005 
PWID leaving rate (cessation+death) per year μ 3.770 4.391 
Factor increase in mortality for 2 weeks following prison release μ* 0.148 0.141 
HCV infection rate amongst λ 
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